Summary
PHARMARIVE has a registered holding activity and consists mainly of financial fixed assets; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €114,888 and a net result of -€19,028. Equity is shrinking by about 6.9% per year across the filed financial years. Its solvency ranks better than 18% of 12,411 sector peers (NACE 47, financial year 2025). The company has been active since 2013 and the Belgian Official Gazette contains no insolvency or warning signals.
Group and network
Holdings and subsidiaries
1 holdingHoldings 1
-
100%
According to the 2024 annual accounts of PHARMARIVE and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
The network starts from this company’s shareholders. What else they own or run appears here as nodes.